Editorials Sulfonylureas as second line treatment for type 2 diabetes BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3041 (Published 18 July 2018) Cite this as: BMJ 2018;362:k3041 Article Related content Metrics Responses Peer review Related articles Research Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study Published: 18 July 2018; BMJ 362 doi:10.1136/bmj.k2693 ResearchSulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events See more NHS launches Race and Health Observatory after BMJ’s call to end inequalities BMJ June 01, 2020, 369 m2191; DOI: https://doi.org/10.1136/bmj.m2191 Covid-19: Doctors need proper mental health support, says BMA BMJ June 01, 2020, 369 m2192; DOI: https://doi.org/10.1136/bmj.m2192 Covid-19: Women’s health campaigners sue FDA over access to medical abortion pills BMJ June 01, 2020, 369 m2187; DOI: https://doi.org/10.1136/bmj.m2187 Covid-19 hot spots appear across Latin America BMJ June 01, 2020, 369 m2182; DOI: https://doi.org/10.1136/bmj.m2182 Sixty seconds on . . . the clap BMJ June 01, 2020, 369 m2183; DOI: https://doi.org/10.1136/bmj.m2183
